As gene therapies continue to stake their foothold on the clinical trial landscape and comprise the future wave of lifesaving pharmaceuticals, high-quality GMP-grade plasmids are increasingly in demand as critical raw materials. Since their use in gene therapy production is still relatively new, health authority regulation around plasmids can be limited, and due to the demand and costs associated with their manufacturing, GMP-grade plasmid suppliers often have finite capacity.

Fill out the form to download the white paper >>>